Haemonetics (HAE) fundamentals: P/E, valuation, undervalued?
Haemonetics · Health Care · ref. ETF XLV · price $121.72
In short — Haemonetics trades at 58.8× earnings (P/E), 20.9× forward, with a net margin of 7.1 % and revenue growth of +6 %. Read: High P/E (P/E 59 (above average)).
Is Haemonetics stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$121.72+144.6% over range
Oct 14, 25low $48.58 · high $122.06Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
88% recommend buying · 8 analysts
Valuation : High P/E — P/E 59 (above average)
Valuation
58.8
P/E (price/earnings)
20.9
Forward P/E
20.28
PEG
6.6
Price/book (P/B)
$5.5B
Market cap
2.07
EPS
Profitability & growth
7.1 %
Net margin
+6 %
Revenue growth
+3 %
Earnings growth
$1.2B
Total debt
Haemonetics income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $1.2B | $115M | 9.9 % |
| 2024 | $1.3B | $118M | 9.0 % |
| 2025 | $1.4B | $168M | 12.3 % |
| 2026 | $1.3B | $97M | 7.3 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Haemonetics's P/E and is the stock undervalued? What's a good P/E?
Haemonetics's P/E is 58.8 (forward 20.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "High P/E".
Is Haemonetics profitable?
Haemonetics has a net margin of 7.1 % (EPS 2.07). The company is profitable.
Is HAE stock expensive?
Our read: "High P/E" — P/E 59 (above average). Cross-check with growth and sector.
💬 A question about Haemonetics? The JPI assistant answers using our backtest data.
Keep exploring Haemonetics